8-K: Canopy Growth Reports FY2026 Results, Revenue Up 6%

Canopy Growth Corporation announced its fiscal fourth quarter and full-year 2026 financial results, highlighting a 6% increase in consolidated net revenue for the full year to $284.6 million, driven by strong performance in its Canadian medical and adult-use cannabis segments.

Summary

• Canopy Growth reported consolidated net revenue of $71.2 million for the fourth quarter of fiscal 2026, a 10% increase year-over-year, and $284.6 million for the full fiscal year 2026, a 6% increase compared to fiscal 2025.
• Cannabis net revenue for Q4 FY2026 was $54.5 million (up 20% year-over-year), and $213.9 million for the full year (up 15% year-over-year).
• Canadian medical cannabis net revenue saw a 27% increase in Q4 FY2026 to $25.3 million and an 18% increase for the full year to $90.8 million.
• Canadian adult-use cannabis net revenue increased 1% in Q4 FY2026 to $20.6 million and 20% for the full year to $94.5 million.
• International markets cannabis net revenue grew 68% in Q4 FY2026 to $8.6 million, though it decreased 7% for the full year to $28.7 million.
• Storz & Bickel net revenue decreased by 14% in both Q4 FY2026 ($16.8 million) and the full year ($70.7 million).
• The company ended the fiscal year with $131.3 million in net cash, a significant improvement from a net debt of $172.6 million at the end of FY2025, following a strategic recapitalization in January 2026.
• Canopy Growth expects to achieve positive Adjusted EBITDA in fiscal year 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with significant improvements in financial position and revenue growth in key segments, but ongoing challenges in others and a continued focus on achieving profitability.

Positives

• Consolidated net revenue increased by 10% in Q4 FY2026 and 6% for the full fiscal year 2026.
• Canadian medical cannabis net revenue grew by 27% in Q4 FY2026 and 18% for the full year.
• Canadian adult-use cannabis net revenue increased by 20% for the full fiscal year 2026.
• International markets cannabis net revenue saw a significant 68% increase in Q4 FY2026.
• The company completed the acquisition of MTL Cannabis, positioning it as Canada's leading medical cannabis company by revenue.
• Net cash position improved to $131.3 million at the end of FY2026, a substantial increase from net debt of $172.6 million at the end of FY2025.
• Net loss from continuing operations narrowed by 21% in Q4 FY2026 and 49% for the full fiscal year 2026.
• Adjusted EBITDA loss improved by 32% in Q4 FY2026 and 14% for the full fiscal year 2026.

Negatives

• Consolidated gross margin decreased from 16% in Q4 FY2025 to 12% in Q4 FY2026, and from 30% in FY2025 to 24% in FY2026.
• Storz & Bickel net revenue decreased by 14% in both Q4 FY2026 and the full fiscal year 2026.
• Storz & Bickel gross margin decreased from 36% in Q4 FY2025 to 27% in Q4 FY2026, and from 37% in FY2025 to 33% in FY2026.
• The company incurred $10.7 million in inventory charges in Q4 FY2026.
• The company recorded $67.1 million in asset impairment and restructuring costs in FY2026.
• Free cash outflow was $69.1 million in FY2026, an improvement from $176.6 million in FY2025 but still a significant outflow.
• International markets cannabis net revenue decreased 7% for the full fiscal year 2026.

Risks

• Uncertainty regarding the application of U.S. state and federal law to cannabis and hemp products, and potential regulations by U.S. agencies.
• Potential for impairment losses, including write-downs of intangible assets like goodwill.
• Ability to refinance debt on favorable terms and comply with debt covenants.
• Risks associated with the strategy to accelerate entry into the U.S. cannabis market through Canopy USA.
• Potential impact of the rescheduling of medical cannabis under the U.S. Controlled Substances Act.
• Risks related to evolving regulatory landscapes in the United States and Canada.
• Impact of macroeconomic environment, including inflation, interest rates, and trade policy.
• Compliance with environmental, economic, health and safety, and energy regulations.

Future Outlook

Canopy Growth expects to achieve positive Adjusted EBITDA during fiscal year 2027, driven by successful execution of strategic priorities, improvements in gross margin from strengthened cultivation practices, and reduced operating expenses due to ongoing cost discipline and efficiencies implemented in FY2026. Year-over-year improvements are anticipated to be more pronounced in the second half of FY2027 due to ongoing MTL Cannabis integration activities.

Management Comments

• "In fiscal 2026, we reset the business, laid a disciplined foundation, and made deliberate investments, including acquiring MTL Cannabis, that will drive the next phase of growth. We modernized our approach to innovation, and our business structure was optimized around a clear strategy."
• "Looking ahead, the opportunity in front of us is significant. As the leading medical cannabis business in Canada by revenue, we are well positioned to extend that leadership into Europe a market we believe represents enormous long-term opportunity and one where our brands, products and relentless execution give us a real competitive edge."
• "We enter fiscal 2027 with momentum, clarity, and a team that has proven it can execute."
• "The significant strengthening of our balance sheet during fiscal 2026 reduces risk while expanding our strategic flexibility. We took meaningful steps to reduce costs and focus resources where they can drive the best returns, and these efforts are starting to be reflected in our financial results."
• "We are confident we have the right strategy and financial model in place to achieve our goal of delivering positive Adjusted EBITDA during fiscal 2027."

Industry Context

StockSavvy.ai notes that Canopy Growth's reported revenue growth in its Canadian medical and adult-use segments, alongside the strategic acquisition of MTL Cannabis, aligns with broader industry trends of consolidation and specialization within the Canadian cannabis market. The company's focus on expanding into Europe also reflects a common strategy among major cannabis players seeking international growth opportunities.

Stakeholder Impact

• Shareholders: Improved net cash position and a path towards profitability may be viewed positively, but continued net losses and revenue declines in certain segments present ongoing concerns.
• Employees: Restructuring costs suggest potential workforce adjustments, while strategic investments may create new opportunities.
• Customers: Continued product innovation and expansion of offerings in medical and adult-use segments aim to meet consumer demand.
• Suppliers: Increased revenue in key segments could lead to greater demand for raw materials and services.

Next Steps

• Continue integration of MTL Cannabis.
• Focus on extending medical cannabis leadership into Europe.
• Implement strengthened cultivation practices to improve gross margin.
• Maintain ongoing cost discipline and operating expense reductions.
• Achieve positive Adjusted EBITDA during fiscal year 2027.

Key Dates

Recommendation

Canopy Growth shows signs of stabilization with revenue growth in core segments and a significantly improved balance sheet. However, persistent gross margin declines in certain areas, substantial asset impairment charges, and the ongoing need to demonstrate consistent profitability warrant a cautious 'hold' rating until sustained positive trends are evident.

Keywords

Canopy Growth, Cannabis, Financial Results, Revenue, Medical Cannabis, Adult-Use Cannabis, SEC Filing, 8-K